0000000000190523

AUTHOR

Luis Almenar

showing 16 related works from this author

Impact of Circulatory Assistance in the Early Evolution After Heart Transplantation. Unicentric Experience.

2021

ABSTRACT Background Heart transplantation (HT) is the reference treatment for patients with terminal heart failure. In recent years there has been a progressive increase in HT procedures in patients who have a circulatory support (CS). Methods This is a retrospective single-center study of 293 consecutive patients who underwent HT from 2009 to 2018, analyzing the evolution of the 2 cohorts: patients with and without CS as a bridge to HT. Baseline and evolutionary clinical data collected following the usual follow-up protocol were recorded, including clinical events observed during the follow-up 1 year after the procedure. Results The subgroup of patients transplanted with CS showed a higher…

Heart transplantationMechanical ventilationHeart FailureTransplantationmedicine.medical_specialtyMultivariate analysisbusiness.industryIncidence (epidemiology)medicine.medical_treatmentOdds ratiomedicine.diseasePrognosisConfidence intervalHeart failureInternal medicineCirculatory systemmedicineCardiologyHeart TransplantationHumansSurgerybusinessFollow-Up StudiesRetrospective StudiesTransplantation proceedings
researchProduct

Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial

2020

Funding: This work was supported in part by an unrestricted grant from Vifor Pharma and Proyectos de Investigación de la Sección de Insuficiencia Cardiaca 2017 from Sociedad Española de Cardiología. The mechanisms underlying the beneficial effect of ferric carboxymaltose (FCM) in patients with heart failure (HF) and iron deficiency (ID) have not been completely characterized. The Myocardial-IRON trial was a double-blind, randomized trial that evaluated myocardial iron repletion following FCM vs. placebo in 53 patients with HF and ID. In this post hoc analysis, we evaluated whether treatment with FCM was associated with cardiac magnetic resonance changes in left and right ventricular functio…

medicine.medical_specialtyMyocardial ironHeart failureSystolic function030204 cardiovascular system & hematologyPlaceboFERRIC CARBOXYMALTOSElaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineOriginal Research ArticlesPost-hoc analysismedicineDiseases of the circulatory (Cardiovascular) system030212 general & internal medicineOriginal Research ArticleVentricular systolic functionEjection fractionbusiness.industryIron deficiencymedicine.diseaseFerric carboxymaltoseHeart failureRC666-701CardiologyCardiology and Cardiovascular MedicinebusinessESC Heart Failure
researchProduct

Myocardial and Peripheral Lymphocytic Transcriptomic Dissociation of β-adrenoceptors and G Protein–coupled Receptor Kinases in Heart Transplantation

2009

Background The genetic expression of adrenergic receptors plays an important pathophysiologic role in heart failure. G protein–coupled receptor kinases (GRKs) desensitize the β-receptor to catecholaminergic stimulation. It has been suggested that their mRNA expression in peripheral lymphocytes could mirror the changes in their myocardial expression in the failing heart, but this relationship between the myocyte and lymphocyte has not been studied in heart transplantation (HT). The objective of this study was to analyze adrenergic receptor and GRK mRNA expression in myocardium and lymphocytes and their correlation. Methods Twenty-three HT patients without evidence of acute rejection or echoc…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdrenergic receptorBiopsymedicine.medical_treatmentLymphocyteInternal medicineReceptors Adrenergic betamedicineHumansLymphocytesRNA MessengerReceptorHeart transplantationTransplantationG protein-coupled receptor kinasebiologybusiness.industryGene Expression ProfilingMyocardiumBeta adrenergic receptor kinaseHeartMiddle AgedG-Protein-Coupled Receptor Kinasesmedicine.diseaseTransplantationEndocrinologymedicine.anatomical_structureHeart failurebiology.proteinHeart TransplantationSurgeryReceptors Adrenergic beta-2Receptors Adrenergic beta-1Cardiology and Cardiovascular MedicinebusinessThe Journal of Heart and Lung Transplantation
researchProduct

Myocardial and lymphocytic expression of eNOS and nNOS before and after heart transplantation: Relationship to clinical status

2013

Abstract Aims The present study investigates the expression and clinical relevance of the constitutive NO synthases in heart and peripheral blood mononuclear cells (PBMCs) obtained from heart failure patients. Main methods mRNA and protein levels (qRT-PCR and immunoblot) of eNOS and nNOS were determined in: i) Left ventricle (LV, n = 4) and PBMCs (n = 10) from healthy donors; ii) LV, right ventricle (RV) and PBMCs of heart failure (HF) patients (n = 32); and iii) biopsies and PBMCs of the HF patients after cardiac transplant (n = 15). Key findings Expression of constitutive NOS isoforms in heart exhibits wide variability in HF patients, but this variability was not related to aetiology, dis…

Malemedicine.medical_specialtyNitric Oxide Synthase Type IIIHeart Ventriclesmedicine.medical_treatmentCardiac indexNitric Oxide Synthase Type IPeripheral blood mononuclear cellGeneral Biochemistry Genetics and Molecular BiologyPredictive Value of TestsEnosInternal medicinemedicineHumansClinical significanceGeneral Pharmacology Toxicology and PharmaceuticsHeart FailureHeart transplantationbiologybusiness.industryGeneral MedicineMiddle Agedmedicine.diseasebiology.organism_classificationPulmonary hypertensionmedicine.anatomical_structureVentricleHeart failureLeukocytes MononuclearCardiologyHeart TransplantationFemalebusinessLife Sciences
researchProduct

Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation.

2015

Aim: Studying the possible influence of SNPs on efficacy and safety of calcineurin inhibitors upon heart transplantation. Materials & methods: In 60 heart transplant patients treated with tacrolimus or cyclosporine, we studied a panel of 36 SNPs correlated with a series of clinical parameters during the first post-transplantation year. Results: The presence of serious infections was correlated to ABCB1 rs1128503 (p = 0.012), CC genotype reduced the probability of infections being also associated with lower blood cyclosporine concentrations. Lower renal function levels were found in patients with rs9282564 AG (p = 0.003), related to higher blood cyclosporine blood levels. A tendency tow…

AdultGraft RejectionMalemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentRenal functionSingle-nucleotide polymorphismInfectionsKidneyKidney Function TestsGastroenterologyPolymorphism Single NucleotideTacrolimusInternal medicineGenotypeGeneticsmedicineHumansAgedPharmacologyHeart transplantationGraft rejectionbusiness.industryMiddle AgedTacrolimusTissue DonorsCalcineurinImmunologyCyclosporineMolecular MedicineHeart TransplantationFemalebusinessPharmacogeneticsImmunosuppressive AgentsPharmacogenomics
researchProduct

Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure etiology and correlates to clinical variables.

2012

Downregulation of β1- adrenergic receptors (β1-ARs) and increased expression/function of G-protein-coupled receptor kinase 2 (GRK2) have been observed in human heart failure, but changes in expression of other ARs and GRKs have not been established. Another unresolved question is the incidence of these compensatory mechanisms depending on heart failure etiology and treatment. To analyze these questions, we quantified the mRNA/protein expressions of six ARs (α1A, α1B, α1D, β1, β2, and β3) and three GRKs (GRK2, GRK3, and GRK5) in left (LV) and right ventricle (RV) from four donors, 10 patients with ischemic cardiomyopathy (IC), 14 patients with dilated cardiomyopathy (DC), and 10 patients wit…

AdultCardiomyopathy DilatedMalemedicine.medical_specialtyGenotypePhysiologyCardiomyopathyMyocardial IschemiaVentricular Function LeftPhysiology (medical)Internal medicinemedicineHumansRNA MessengerHeart FailureAnalysis of VarianceEjection fractionIschemic cardiomyopathybiologybusiness.industryBeta adrenergic receptor kinaseMyocardiumDilated cardiomyopathyStroke VolumeStroke volumeMiddle Agedmedicine.diseaseG-Protein-Coupled Receptor KinasesReceptors AdrenergicEndocrinologymedicine.anatomical_structurePhenotypeVentricleSpainHeart failurebiology.proteinCardiologyLinear ModelsFemaleCardiology and Cardiovascular MedicinebusinessCardiomyopathiesAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron : The Myocardial- Trial

2020

Background Intravenous ferric carboxymaltose ( FCM ) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after FCM administration in patients with heart failure and iron deficiency using cardiac magnetic resonance. Methods and Results Fifty‐three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive intravenous FCM or placebo in a multicenter, double‐blind study. T2* and T1 mapping cardiac magnetic resonance sequences, noninvasive surrogates of intramyocardial iron, were eval…

MaleCardiac magnetic resonance*ferric carboxymaltoseMagnetic Resonance Imaging (MRI)Myocardial ironAnèmia*heart failure030204 cardiovascular system & hematologyFerric Compounds0302 clinical medicine030212 general & internal medicineOriginal Researchcardiac magnetic resonance ferric carboxymaltose heart failure iron deficiency myocardial ironAnemia Iron-DeficiencyAnemiaIron deficiencyMiddle AgedMyocardial ironMagnetic Resonance Imaging*myocardial ironMagnetic resonanceCardiologyAdministration IntravenousFemaleCardiology and Cardiovascular Medicine*cardiac magnetic resonancemedicine.medical_specialtyNoninvasive imagingCardiomyopathyIronIntravenous ironHeart failureFERRIC CARBOXYMALTOSE03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltoseAgedPharmacologybusiness.industryMyocardiumIron deficiencyRessonància magnèticaMiocardimedicine.diseaseFerric carboxymaltoseTreatmentHeart failureHematinicsbusinessCardiac magnetic resonance*iron deficiencyFerro
researchProduct

Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population

2013

Interpatient variability in drug response can be widely explained by genetically determined differences in metabolizing enzymes, drug transporters, and drug targets, leading to different pharmacokinetic and/or pharmacodynamic behaviors of drugs. Genetic variations affect or do not affect drug responses depending on their influence on protein activity and the relevance of such proteins in the pathway of the drug. Also, the frequency of such genetic variations differs among populations, so the clinical relevance of a specific variation is not the same in all of them. In this study, a panel of 33 single nucleotide polymorphisms in 14 different genes (ABCB1, ABCC2, ABCG2, CYP2B6, CYP2C19, CYP2C…

GenotypeCYP2B6Nod2 Signaling Adaptor ProteinOrganic Anion TransportersSingle-nucleotide polymorphismCYP2C19PharmacologyPolymorphism Single NucleotideWhite PeopleCytochrome P-450 Enzyme SystemGene FrequencyGenetic variationGenotypeHumansPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1GlucuronosyltransferaseAllele frequencyCYP2C9Methylenetetrahydrofolate Reductase (NADPH2)PharmacologyGeneticsbiologyMethyltransferasesMultidrug Resistance-Associated Protein 2Tissue DonorsTransplant RecipientsSpainInactivation MetabolicUDP-Glucuronosyltransferase 1A9biology.proteinSLCO1B1Immunosuppressive AgentsTherapeutic Drug Monitoring
researchProduct

β2- and β1-Adrenoceptor Expression Exhibits a Common Regulatory Pattern With GRK2 and GRK5 in Human and Animal Models of Cardiovascular Diseases.

2015

To explore if genic expression of β(1)- or β(2)-adrenoceptors (ARs) exhibits a common regulatory pattern with G protein-coupled receptor kinase (GRK) 2, GRK3, or GRK5 expression, we determined messenger RNA levels for these genes in different tissues from human and animal models of cardiovascular disease. We measured genic expression by qRT polymerase chain reaction in the left and right ventricles or peripheral blood mononuclear cells from healthy (n = 21), hypertensive (n = 20), heart failure (n = 24), and heart transplanted patients (n = 17) or in left ventricle, peripheral blood mononuclear cells, and kidney from spontaneously hypertensive rats or L-N-methyl-arginine-induced hypertensiv…

G-Protein-Coupled Receptor Kinase 5medicine.medical_specialtyG-Protein-Coupled Receptor Kinase 2Heart DiseasesBiologyPeripheral blood mononuclear cellRats Inbred WKYInternal medicineRats Inbred SHRmedicineAnimalsHumansRNA MessengerReceptorGenePharmacologyRegulation of gene expressionMessenger RNAG protein-coupled receptor kinaseKinaseBeta adrenergic receptor kinaseDisease Models AnimalEndocrinologyNG-Nitroarginine Methyl EsterGene Expression RegulationOrgan SpecificityCase-Control StudiesHypertensionbiology.proteinReceptors Adrenergic beta-2Receptors Adrenergic beta-1Cardiology and Cardiovascular MedicineJournal of cardiovascular pharmacology
researchProduct

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

2018

Post-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients. PTLD had an earlier onset in allo-HSCT than in SOT cohort (4 vs. 64 months, p  .0001). PTLD was EBV-positive in 100% of allo-HSCT, in co…

AdultGraft RejectionMaleCancer ResearchPathologymedicine.medical_specialtyEpstein-Barr Virus InfectionsHerpesvirus 4 HumanTransplantation ConditioningAdolescentmedicine.medical_treatmentLymphoproliferative disordersHematopoietic stem cell transplantationmedicine.disease_causeSingle Center03 medical and health sciencesYoung Adult0302 clinical medicineEpstein–Barr virus Solid organ transplantation hematopoietic stem cell transplantation immunosuppression post-transplant lymphoproliferative disordershemic and lymphatic diseasesmedicineHumansTransplantation HomologousRetrospective Studiesbusiness.industryHematopoietic Stem Cell TransplantationImmunosuppressionHematologyOrgan TransplantationMiddle Agedmedicine.diseaseEpstein–Barr virusSurvival AnalysisPost transplantLymphoproliferative Disorderssurgical procedures operativeOncology030220 oncology & carcinogenesisFemaleVirus ActivationSolid organLymph NodesbusinessComplication030215 immunology
researchProduct

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian …

2022

Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI). Methods: We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were randomized within 5 days of their qualifying MI and received dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor. The effect of asundexian on FXIa inhibition…

MaleTicagrelorAspirinMyocardial InfarctionAnticoagulantsHemorrhageFactor XIaPercutaneous Coronary InterventionTreatment OutcomeDouble-Blind MethodPhysiology (medical)HumansFemale03.02. Klinikai orvostanAcute Coronary SyndromeCardiology and Cardiovascular MedicinePrasugrel HydrochloridePlatelet Aggregation InhibitorsAgedCirculation
researchProduct

Myocardial G Protein Receptor–Coupled Kinase Expression Correlates With Functional Parameters and Clinical Severity in Advanced Heart Failure

2010

In heart failure (HF), sympathetic hyperactivation induces deleterious effects in myocardial β-adrenergic signaling, with receptor down-regulation and desensitization mediated by G protein receptor-coupled kinases (GRKs). We hypothesised that changes in GRK isoforms may be associated with clinical status in advanced HF, using the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) scale.We included 31 patients with advanced HF undergoing transplantation. According to INTERMACS profiles, mRNA and protein levels of GRK isoforms in left ventricular (LV) myocardium were analyzed and compared with nonfailing LV samples.In failing LV myocardium, GRK2 and GRK5 (but not G…

G-Protein-Coupled Receptor Kinase 5Malemedicine.medical_specialtyG-Protein-Coupled Receptor Kinase 2Down-RegulationPolymerase Chain ReactionSeverity of Illness IndexGene Expression Regulation EnzymologicInternal medicinemedicineHumansRNA MessengerRegistriesReceptorG protein-coupled receptorHeart FailureG protein-coupled receptor kinasebiologybusiness.industryMyocardiumBeta adrenergic receptor kinaseStroke volumeMiddle AgedG-Protein-Coupled Receptor Kinasesmedicine.diseaseTransplantationEndocrinologySpainHeart failureCirculatory systembiology.proteinFemaleHeart-Assist DevicesCardiology and Cardiovascular MedicinebusinessJournal of Cardiac Failure
researchProduct

Abstract 16304: Readiness for Physical Activity in Patients With Heart Failure

2020

Introduction: Little attention has been given to assessing the physical readiness and psychological readiness (motivation & self-efficacy) in patients with heart failure (HF). The aim of this study is to explore the readiness for PA (physical and psychological) in patients with HF and factors related. Method: A cross-sectional study with 163 patients included (mean age 66±16, 50% female, 63% NYHA I, 37% NYHA II) assessing background and clinical data, physical activity (IPAQ-s), depression and anxiety (HADs), quality of life (SF36). Readiness for PA was assessed with physical readiness based on the PA Readiness Questionnaire (PAR-Q) and psychological readiness was measured with the Exe…

medicine.medical_specialtyRehabilitationbusiness.industrymedicine.medical_treatmentPhysical activitymedicine.diseasePhysiology (medical)Heart failurePhysical therapymedicineIn patientCardiology and Cardiovascular MedicinebusinessCardiovascular nursingCirculation
researchProduct

Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.

2016

Cytomegalovirus (CMV) infection remains a major complication of solid organ transplantation. Because of management of CMV is variable among transplant centers, in 2011 the Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) developed consensus guidelines for the prevention and treatment of CMV infection in solid organ transplant recipients. Since then, new publications have clarified or questioned the aspects covered in the previous document. For that reason, a panel of experts revised the evidence on CMV management, including immunological monitoring, diagnostics, prevention, vaccines, indirect effects, tre…

medicine.medical_specialtyCongenital cytomegalovirus infectionMEDLINEDrug resistance030230 surgeryAntiviral AgentsOrgan transplantation03 medical and health sciences0302 clinical medicineMonitoring ImmunologicMedicineHumansMajor complicationIntensive care medicineTransplantationbusiness.industryOrgan Transplantationmedicine.diseaseTransplant RecipientsCytomegalovirus infectionClinical microbiologyImmunologyCytomegalovirus InfectionsPractice Guidelines as Topic030211 gastroenterology & hepatologybusinessSolid organ transplantationTransplantation reviews (Orlando, Fla.)
researchProduct

Activation of α1A-adrenoceptors desensitizes the rat aorta response to phenylephrine through a neuronal NOS pathway, a mechanism lost with ageing

2017

Background and purpose A NO-mediated desensitization of vasoconstrictor responses evoked by stimulation of α1 -adrenoceptors has been reported in different vessels. We investigated the involvement of each α1 -adrenoceptor subtype and constitutive NOS isoforms and the influence of ageing and hypertension on this process. Experimental approach Wistar and spontaneously hypertensive rats (SHR), 16, 32, 52 and 72 weeks-old, were used to evaluate the desensitization process. Expression of α1 -adrenoceptor subtypes, endothelial NOS (eNOS) and neuronal NOS (nNOS) were determined in rat aorta and left ventricle (LV). Expression levels were also evaluated in LV of a group of heart failure patients wi…

0301 basic medicinePharmacologymedicine.medical_specialtyAortaAdrenergic receptorEndotheliumbusiness.industryAdrenergic030204 cardiovascular system & hematologyEndothelial NOS03 medical and health sciences030104 developmental biology0302 clinical medicineEndocrinologymedicine.anatomical_structureDesensitization (telecommunications)Internal medicinemedicine.arterycardiovascular systemmedicinemedicine.symptombusinessPhenylephrineVasoconstrictionmedicine.drugBritish Journal of Pharmacology
researchProduct

Changes in myocardial iron content following administration of intravenous iron (Myocardial‐IRON): Study design

2018

Treatment with intravenous ferric carboxymaltose (FCM) has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure and iron deficiency. However, the underlying mechanisms for these beneficial effects remain undetermined. The aim of this study is to quantify cardiac magnetic resonance changes in myocardial iron content after administration of intravenous FCM in patients with heart failure and iron deficiency and contrast them with parameters of heart failure severity. This is a multicenter, double-blind, randomized study. Fifty patients with stable symptomatic heart failure, left ventricular ejection fraction <50%, and iron deficiency will be r…

MaleTime FactorsMyocardial ironheart failure030204 cardiovascular system & hematologyFerric CompoundsSeverity of Illness IndexVentricular Function Left030218 nuclear medicine & medical imaginglaw.invention0302 clinical medicineiron deficiencyClinical ProtocolsQuality of lifeRandomized controlled triallawCardiac Magnetic Resonance Ferric Carboxymaltose Heart Failure Iron Deficiency Myocardial IronInfusions IntravenousEjection fractionAnemia Iron-DeficiencyGeneral MedicineIron deficiencyferric carboxymaltoseTreatment OutcomeResearch DesignCardiologyFemaleCardiology and Cardiovascular MedicineCardiac function curvemedicine.medical_specialtyTrial DesignsMagnetic Resonance Imaging CinePlacebocardiac magnetic resonance03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltosemyocardial ironAgedHeart Failurebusiness.industryMyocardiumStroke VolumeRecovery of Functionmedicine.diseaseSpainHeart failureHematinicsQuality of Lifebusiness
researchProduct